Unit
Genome Integrity, RNA and Cancer (UMR3348)
Thematic areas of research:
Image
To top
Unit
STEPHAN VAGNER / SARAH LAMBERT
Genome Integrity, RNA and Cancer (UMR3348)
The research conducted at the « Genome Integrity, RNA and Cancer » Unit explores multiple aspects of genome dynamics that integrate RNA biology in the context of genome maintenance and expression in normal and pathological situations, including cancer.
Teams
Key figures
25
km from Paris
25
nationalities since 2015
25
INTERNATIONAL EVENTS ORGANISED
Key publications
All publications
-
-
-
The plasticity of mRNA translation during cancer progression and therapy resistanceNature Reviews Cancer
-
-
-
-
-
Proper chromosome alignment depends on BRCA2 phosphorylation by PLK1Nature Communications
-
-
-
Cytidine Deaminase Deficiency Reveals New Therapeutic Opportunities against CancerClinical Cancer Research
-
-
News
All news
-
Dr. Albertas Navickas, winner of the prix Ruban Rose Avenir 2023Dr. Albertas Navickas, head of the RNA, Tumor Microenvironment and Metastasis team in the Genome integrity, RNA and Cancer unit (CNRS UMR3348/University Paris-Saclay), was recognized by the Ruban Rose association for his promising project on communication between cancer cells of the breast and the cells of the lungs.24/10/2023 -
New major players in the protection of DNA replication forks are identifiedIn an article published on March 2, 2023, in the journal Molecular Cell, the team led by Sarah Lambert, in collaboration with researchers from the Institute for Integrative Biology of the Cell, revealed a mechanism that ensures the integrity of DNA replication forks. Based on the combination of RNA and the end-joining factor Ku, it represents a potential new therapeutic target to fight cancerous cells.13/03/2023 -
Three research projects at Institut Curie financed by the ERC Synergy GrantThree projects at Institut Curie are laureate of the highly selective and prestigious Synergy Grant 2022 program, awarded by the European Research Council. These three grants, for an amount of 10 million euros each, shine a light on Institut Curie’s excellence and its teams in cellular biology. A breakthrough field to further the fight against cancer.28/10/2022 -
Carsten Janke awarded an ERC Advanced GrantLong-neglected, research on post-translational modifications of microtubules is now a promising field, thanks in particular to Carsten Janke, a world expert in this area. His excellence in this discipline and the hopes placed in his research have been recognized by the European Research Council (ERC).12/08/2022 -
Albertas Navickas, using organoids to better understand metastatisNewly arrived at Institut Curie, Albertas Navickas, a new Junior Principal Investigator, is working on breast cancer and preparing to form an RNA, tumor microenvironment and metastasis team, reporting to the Genome integrity, RNA and Cancer unit (CNRS UMR3348/University Paris-Saclay), at Orsay.03/05/2022 -
Aglaia Therapeutics devient Ribonexus et signe avec Pierre Fabre un accord de licence exclusif portant sur de petites molécules ciblant la protéine eIF4A, une nouvelle cible en oncologieRibonexus (anciennement Aglaia Therapeutics), une entreprise de biotechnologie développant de nouveaux traitements capables de contrer la résistance aux thérapies ciblées chez les patients atteints de cancer, et le groupe pharmaceutique français Pierre Fabre annoncent aujourd’hui la signature d’un accord de licence exclusif portant sur une série de petites molécules brevetées par Pierre Fabre qui ciblent le facteur d’initiation eukaryotique de la traduction 4A (eIF4A). Fortement exprimée dans plusieurs cancers solides et hématologiques, notamment le mélanome, cette cible est associée à une résistance à de nombreuses thérapies actuelles.18/11/2021
Scientific events
All scientific events
15 Sep
2023
Orsay seminar series
11h-23h
Exploiting self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress
I will present two discoveries from my team dealing with precision medicine approaches and possibilities. The first part deals with widely used genotoxic cancer therapy, such as irradiation. These modalities operate through extensive induction of DNA breaks, yet cancer cells frequently display resistance to such interventions. Intriguingly, studies following the dynamics of radiation-induced DNA l
11 Jul
2023
Institutional seminar "Mayent - Rothschild"
11h-23h
Melanoma metastatic niche formation: extracellular vesicles, miRNA, immune, CAF and more
Melanoma initiate at the epidermis and become metastatic once invade into the dermis. We present mutation independent trigger of melanoma switch into the invasive dermal phenotype from the radial dermal growth. We further showed how melanoma cells shape the tumor microenvironment by the trafficking of miRNA via large extracellular vesicles. In recent work we found melanoma interactions with
3 Jul
2023
Orsay seminar series
11h-23h
Microtubule Methylation: The Second Language of Chromatin Readers, Writers and Erasers
Dr. Cheryl Lyn Walker directs the Center for Precision Environmental Health at Baylor College of Medicine, where she holds the Alkek Presidential Chair in Environmental Health. Her research focuses on the epigenetic machinery responsible for “reading, writing and erasing” histone modifications, and the newly discovered role for this machinery outside the nucleus, where it acts di
15 Dec
2022
Seminar
11h-12h
Advances on Human Topoisomerases IIIA and IIIB, the Most Ancestral and Least Known Topoisomerases
Human cells encode 6 topoisomerases to regulate the topology of nucleic acids. While yeast has only one Top3, mammals encode two Type IA topoisomerases: topoisomerase III alpha (TOP3A) and topoisomerase III beta (TOP3B). We will review the importance of these two enzymes and present new insights on their biochemistry, molecular structure, and biological functions for replicating the nuclear and mi
23 Nov
2022
Seminar
11h-23h
Seeing is believing: break-induced mitotic recombination from 1936 to 2022
And online: Click here to join by Teams